CRNO-B.ST
SinkerCereno Scientific AB (publ) · Healthcare · Sweden · $97M cap · $188K/day traded
SEK 0.1585 +17.1% · close 18 Nov · scored 19 Nov
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 19 Nov 2026, the MoatMap Score for Cereno Scientific AB (publ) (CRNO-B.ST) is 6/100, ranked against 25,000+ stocks in 38 markets (Quality 22, Value 36, Momentum 18, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT CERENO SCIENTIFIC AB (PUBL)
Read
Cereno Scientific AB is a clinical-stage biotechnology company developing innovative disease-modifying therapies for rare cardiovascular diseases, with a primary focus on Pulmonary Arterial Hypertension (PAH). The company's lead drug candidate, CS1, utilizes epigenetic modulation to offer a novel treatment approach, supported by a strategic collaboration with global medical device leader Abbott. Cereno's competitive position is reinforced by a robust patent portfolio and orphan drug designations in major global markets.
FINANCIAL SUMMARY (SEK)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Income and shares | |||||||||
| Revenue | — | — | — | — | — | — | — | — | — |
| Net margin | n/m | n/m | n/m | n/m | — | — | — | — | — |
| EPS (SEK) | -0.09 | -0.21 | -0.35 | -0.38 | — | -0.41 | -0.44 | -0.55 | — |
| Share count | 311.4M | 233.8M | 281.7M | 310.5M | -0.1% | 323.1M | — | — | — |
| Balance sheet | |||||||||
| Debt | 0.4M | 45.4M | 190.4M | 125.0M | 578.6% | 176.0M | — | — | — |
| Equity | 201.5M | 216.4M | 191.9M | 252.6M | 7.8% | — | — | — | — |
| Debt/equity | 0.0x | 0.2x | 1.0x | 0.5x | +0.5x | — | — | — | — |
| Cash flow | |||||||||
| Op. cash flow | -18.6M | -36.9M | -103.4M | -111.9M | — | -71.0M | — | — | — |
| Cash flow margin | n/m | n/m | n/m | n/m | — | — | — | — | — |
| Investing CF | -57.5M | -49.3M | -84.8M | -44.3M | — | — | — | — | — |
| Financing CF | 53.6M | 106.3M | 228.6M | 103.3M | — | — | — | — | — |
Cash on hand equals about 7 months of the operating cash used in the last twelve months. Spending on equipment or exploration and any new funding are not counted.
Made a new 52-week low in the latest session, 98% below its 52-week high. The fall has not stopped yet.
Swung more than 97% of stocks we rank over the past year (volatility 115% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling (this stock): It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRNO-B.ST are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| CRNO-B.ST | Cereno Scientific AB (publ)(you) | $97M | 6 |
| DICOT.ST | Dicot Pharma AB | $75M | 9 |
| CINPHA.ST | Cinclus Pharma Holding AB (publ) | $55M | 7 |
| ORX.ST | Orexo AB (publ) | $55M | 11 |
| EQL.ST | EQL Pharma AB (publ) | $59M | 20 |
| MOB.ST | Moberg Pharma AB (publ) | $52M | 31 |
| NANEXA.ST | Nanexa AB (publ) | $205M | 69 |
| MVIR.ST | Medivir AB (publ) | $94M | 6 |
| EPIS-B.ST | Episurf Medical AB (publ) | $100M | 6 |
| SYNACT.ST | SynAct Pharma AB | $97M | 10 |
Peer medians: ROE 5.7% · P/E 32.6x · Gross margin 68.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.